GamaMabs Pharma’s lead drug, GM102, has been granted Orphan Drug Designation by the US Food and Drug Administration (FDA).   GM102 is a first-in-class monoclonal antibody targeting AMHR2-expressing tumors. It exerts its anti-tumor activity through macrophage engagement resulting in tumor phagocytosis. The first-in-human GM102 Phase Ia/Ib trial is ongoing in gynecological cancers, with initial results expected in the first half of this year.   “We are delighted that our lead drug,...